These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20026740)

  • 1. Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells.
    Lundqvist A; Su S; Rao S; Childs R
    J Immunol; 2010 Feb; 184(3):1139-42. PubMed ID: 20026740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
    Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
    Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
    Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
    Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
    Schumacher LY; Vo DD; Garban HJ; Comin-Anduix B; Owens SK; Dissette VB; Glaspy JA; McBride WH; Bonavida B; Economou JS; Ribas A
    J Immunol; 2006 Apr; 176(8):4757-65. PubMed ID: 16585569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
    Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
    Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bortezomib enhances the sensitivity of prostate cancer cells to natural killer cell-mediated cytotoxicity].
    Hu W; Gao ZY; Wang W
    Zhonghua Nan Ke Xue; 2014 Mar; 20(3):218-24. PubMed ID: 24738457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
    Lundqvist A; Yokoyama H; Smith A; Berg M; Childs R
    Blood; 2009 Jun; 113(24):6120-7. PubMed ID: 19202127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL.
    Bakker AB; Phillips JH; Figdor CG; Lanier LL
    J Immunol; 1998 Jun; 160(11):5239-45. PubMed ID: 9605119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
    Ames E; Hallett WH; Murphy WJ
    Clin Exp Immunol; 2009 Mar; 155(3):504-13. PubMed ID: 19220837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
    Hu W; Zheng RR; Cui HX; Yue D; Wang Y; Jiang YH
    Asian J Androl; 2012 Sep; 14(5):695-702. PubMed ID: 22902909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
    Hallett WH; Ames E; Motarjemi M; Barao I; Shanker A; Tamang DL; Sayers TJ; Hudig D; Murphy WJ
    J Immunol; 2008 Jan; 180(1):163-70. PubMed ID: 18097016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
    Seeger JM; Schmidt P; Brinkmann K; Hombach AA; Coutelle O; Zigrino P; Wagner-Stippich D; Mauch C; Abken H; Krönke M; Kashkar H
    Cancer Res; 2010 Mar; 70(5):1825-34. PubMed ID: 20179203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
    Straube C; Wehner R; Wendisch M; Bornhäuser M; Bachmann M; Rieber EP; Schmitz M
    Leukemia; 2007 Jul; 21(7):1464-71. PubMed ID: 17495970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
    Seo N; Tokura Y; Takigawa M; Egawa K
    J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of sublines selected for loss of HLA expression from an EBV-transformed lymphoblastoid cell line. Changes in sensitivity to cytotoxic T cells activated by allostimulation and natural killer cells activated by IFN or IL-2.
    Ohlén C; Bejarano MT; Grönberg A; Torsteinsdottir S; Franksson L; Ljunggren HG; Klein E; Klein G; Kärre K
    J Immunol; 1989 May; 142(9):3336-41. PubMed ID: 2468716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones.
    Uzana R; Eisenberg G; Sagi Y; Frankenburg S; Merims S; Amariglio N; Yefenof E; Peretz T; Machlenkin A; Lotem M
    J Immunol; 2012 Jan; 188(2):632-40. PubMed ID: 22156347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing.
    Gregerson DS; Lew KL; McPherson SW; Heuss ND; Ferrington DA
    Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5385-94. PubMed ID: 17122128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.